spec sheet12 rows
Oleamide (cis-9,10-octadecenoamide) is an endogenous fatty acid primary amide, the simple amide of oleic acid, and the prototypical member of a family of brain lipids that function as biological signaling molecules [1]. It first drew attention when it was isolated from the cerebrospinal fluid of sleep-deprived cats, where it accumulates in proportion to the sleep debt and, when injected into rats, induces physiological sleep [1]. Mechanistically it is a substrate of fatty acid amide hydrolase (FAAH), the same enzyme that degrades the endocannabinoid anandamide, and it modulates cannabinoid, serotonergic, GABAergic, and gap-junction signaling [2][3][4][5]. In the supplement market it is sold as a sleep and relaxation aid, although controlled human evidence remains thin and most of what is known derives from cell and rodent work [6][13].
- Promotes sleep onset; in animals it shortens sleep latency and produces genuine behavioral and EEG signs of physiological sleep rather than sedation-only anesthesia [1][8].
- May ease anxiety and promote calm through combined GABA-A potentiation and cannabinoid-like signaling, consistent with its inhibitory, relaxing pharmacology [5][13].
- Prolongs endocannabinoid tone by competing with anandamide for FAAH, an entourage effect that can amplify the body's own cannabinoid signaling [2][13].
- Modulates serotonergic signaling as an allosteric potentiator at 5-HT2 and 5-HT7 receptors, a mechanism tied to mood and arousal [3].
- Drowsiness and reduced alertness are the most likely effects given its sleep-inducing, locomotor-suppressing action in animals.
- Additive sedation is plausible when combined with alcohol, benzodiazepines, cannabis, or other sleep aids.
Overview
Oleamide is the primary (unsubstituted) amide of the monounsaturated fatty acid oleic acid, bearing a single cis double bond at the 9,10 position of an eighteen-carbon chain and a terminal carboxamide in place of the carboxylic acid. It belongs to the class of fatty acid primary amides (FAPAs), long-chain lipids that end in a simple CONH2 group rather than an ester or an ethanolamide, and it is regarded as the best characterized member of that family [1][6]. The cis geometry of the double bond is essential; the trans isomer and the parent oleic acid are largely inactive in the assays that define oleamide's biology, underscoring that its effects reflect a specific structural signal rather than a generic lipid property [13].
The compound entered the scientific record in 1995, when a molecule purified from the cerebrospinal fluid of sleep-deprived cats was chemically identified as cis-9,10-octadecenoamide and shown to induce sleep in rats; the same study reported that a broader set of fatty acid primary amides are natural constituents of cat, rat, and human cerebrospinal fluid, suggesting a previously unrecognized class of signaling lipids [1]. Follow-up work confirmed that endogenous oleamide concentrations in cerebrospinal fluid rise several fold during sustained sleep deprivation and fall with recovery sleep, consistent with a role as an endogenous sleep-pressure factor [8].
Biosynthesis is thought to proceed from oleic acid through an N-acyl glycine intermediate; oleic acid is activated to oleoyl-CoA, conjugated to glycine to form N-oleoylglycine, and then oxidatively cleaved to the primary amide, a reaction attributed to peptidylglycine alpha-amidating monooxygenase (PAM), the same enzyme that amidates neuropeptides [11][14]. The long-chain N-acylglycine intermediate is generated by a glycine N-acyltransferase-like enzyme (GLYATL3) [14], though the pathway remains debated and N-oleoylglycine appears to carry biological activity of its own [12]. Signal termination is enzymatic: FAAH hydrolyzes oleamide back to inactive oleic acid, so tissue and cerebrospinal fluid levels are set by the balance of synthesis and FAAH-mediated degradation [2][9]. Commercially, oleamide is produced synthetically and sold both as an industrial slip agent in plastics and as an over-the-counter capsule marketed for sleep and calm [6].
- Oleamide was literally fished out of the spinal fluid of sleep-deprived cats; it builds up as sleep debt accumulates and, injected into rats, puts them to sleep, making it one of the few real molecular candidates for an endogenous sleep factor [1][8].
- The enzyme that keeps the brain's cannabinoid anandamide in check, fatty acid amide hydrolase, was first discovered as oleamide hydrolase; oleamide was the substrate that revealed it [2].
- Oleamide is one of the earliest known allosteric modulators of a serotonin G-protein-coupled receptor, potentiating 5-HT2A signaling and acting at a distinct site on the 5-HT7 receptor rather than the usual serotonin pocket [3].
- Unlike most lipids, oleamide selectively shuts down gap-junction communication between glial cells while leaving their calcium-wave signaling intact, a rare and specific action linked to how it might trigger sleep [4].
- Only the natural cis form is active; the trans isomer and plain oleic acid are largely inert, so a single kink in an eighteen-carbon chain is what turns a fatty acid into a sleep signal [13].
Mechanism
Oleamide's defining action is as an endogenous sleep-inducing lipid. Isolated from the cerebrospinal fluid of sleep-deprived cats and structurally identified as cis-9,10-octadecenoamide, it induces physiological sleep when administered to rats, shortening sleep latency and suppressing locomotor activity while producing behavioral and electroencephalographic signs of natural sleep rather than anesthesia [1][8]. Endogenous concentrations track sleep pressure, rising three- to four-fold in cerebrospinal fluid after sustained wakefulness and declining after recovery sleep, which places oleamide among the small set of molecules with a credible claim to being a physiological sleep factor [8]. Its clearance is governed by the choroid plexus and ventricular epithelium, where FAAH is positioned to regulate cerebrospinal-fluid oleamide levels and thereby shape the magnitude and duration of its hypnotic effect [9].
At the enzymatic level, oleamide was in fact the substrate through which fatty acid amide hydrolase was first discovered. The activity originally named oleamide hydrolase was cloned from rat liver and shown to hydrolyze not only oleamide but also anandamide, the endogenous cannabinoid , converting each fatty acid amide to its inactive acid; the enzyme was accordingly renamed fatty acid amide hydrolase in recognition of the growing family of substrates it degrades [2]. Because oleamide and anandamide compete for the same catabolic enzyme, oleamide can prolong anandamide signaling simply by occupying FAAH, a form of substrate competition often invoked as an entourage effect in which a co-released, weakly active congener protects the primary endocannabinoid from hydrolysis [13]. This indirect route is thought to underlie much of oleamide's cannabimimetic character.
The relationship to the cannabinoid CB1 receptor is genuinely mixed. Oleamide produces cannabinoid-like behavioral effects, and some studies describe direct, albeit weak, actions at CB1, while others attribute its effects mainly to FAAH inhibition and the resulting elevation of anandamide, and still others document CB1-independent actions entirely [13]. In rat glioblastoma cells, for instance, oleamide triggered apoptotic cell death through a mechanism that persisted when CB1 and CB2 receptors were blocked, showing that not all of its biology runs through the classical cannabinoid receptors [15]. The practical picture is of a compound that behaves cannabimimetically in vivo but is at best a weak direct CB1 , with the endocannabinoid tone it borrows from anandamide doing much of the work.
A second signaling axis is serotonergic and, unusually, . In cells expressing the receptor, oleamide potentiates -evoked phosphoinositide hydrolysis, and at the 5-HT7 receptor it acts at an apparent allosteric site, evoking cyclic AMP responses on its own while antagonizing the effect of serotonin, a dual behavior that marked one of the first descriptions of allosteric regulation of a G-protein-coupled monoamine receptor [3]. This positive modulation of 5-HT2-family signaling, extended in the literature to the 5-HT2C subtype, links oleamide to the serotonergic control of arousal and mood, and recent structural modeling has mapped a putative oleamide pocket on that overlaps the binding site of cannabidiol [16][13].
Oleamide also targets the -A receptor. In cultured cortical neurons it enhances responses to sub-saturating GABA, increasing the affinity of the receptor for its and prolonging inhibitory postsynaptic currents; the effect requires a gamma-2 subunit but is insensitive to the benzodiazepine flumazenil, identifying a distinct site on GABA-A isoforms important for arousal and the circadian control of sleep [5]. Oleic acid itself is inactive in these assays, again pointing to a specific, structure-dependent interaction rather than a nonspecific membrane effect [5]. Through this potentiation, oleamide reinforces inhibitory tone in a manner complementary to its serotonergic and cannabinoid actions, and it has been examined, with weak results, as a possible endogenous anticonvulsant [10].
Finally, oleamide possesses a mechanism that is rare among neuroactive lipids: it blocks gap-junction communication between glial cells. It potently and selectively uncouples gap-junction-mediated dye transfer between rat while sparing mechanically stimulated intercellular calcium waves, in contrast to traditional gap-junction blockers that suppress both [4]. Because intercellular coupling among astrocytes is implicated in the synchronization of neuronal networks and in circadian and sleep-related signaling, this connexin-directed action offers a distinctive route by which oleamide could influence higher-order events such as sleep induction, independent of its receptor pharmacology [4][6].
receptor fingerprint
Gap junctions (connexin)blocker
positive allosteric modulator
5-HT7allosteric agonist / modulator
-Apositive allosteric modulator
CB1weak/indirect agonist
5-HT2Cpositive allosteric modulator
FAAHsubstrate
Safetyrisks and cautions, not medical advice
Oleamide is an endogenous lipid that the body already makes and degrades, and it is sold over the counter as a sleep and relaxation supplement, but its human safety profile is not well defined and no rigorous clinical trials establish safe doses or long-term effects. The most predictable effect from its pharmacology is sedation; because it induces sleep and suppresses locomotor activity in animals, users should treat it as potentially drowsiness-inducing and avoid driving or operating machinery until they know how they respond [1][8].
Its actions on cannabinoid, serotonergic, and GABAergic systems raise a plausible risk of additive effects with alcohol, benzodiazepines, other sedatives and sleep aids, cannabis, and serotonergic drugs, so combining it with those agents is best avoided without medical guidance [3][5][13]. Much of what is sold is the same synthetic oleamide used industrially as a plastics slip agent, so purity and dosing accuracy vary by source. There is no established safety data for pregnancy, breastfeeding, or use in people with medical conditions, and anyone taking prescription medication should consult a clinician first. In short, it is an interesting endogenous molecule with a thin human safety record, and expectations should be modest and cautious.
History
Oleamide's story begins with a hunt for the chemical basis of sleep. Building on the century-old hypnotoxin hypothesis that wakefulness generates a sleep-promoting substance, a team at the Scripps Research Institute led by Richard Lerner, with Benjamin Cravatt and the chemist Dale Boger, isolated a lipid that accumulated in the cerebrospinal fluid of sleep-deprived cats. In a 1995 paper in Science they identified it as cis-9,10-octadecenoamide, showed that synthetic material induced physiological sleep in rats, and reported that related fatty acid primary amides were natural constituents of cat, rat, and human cerebrospinal fluid, proposing them as a new class of signaling molecules [1]. The discovery was notable both for the elegance of the chemistry and for reviving a long-standing question in sleep science with a concrete molecular candidate.
The same laboratory soon turned to how the signal is switched off. In 1996 they cloned the enzyme they had first called oleamide hydrolase, found that it also degrades anandamide, and renamed it fatty acid amide hydrolase in recognition of the breadth of substrates it accepts, tying oleamide directly to the emerging biology of the endocannabinoid system [2]. Over the following decade oleamide's pharmacology was mapped onto serotonin receptors, where it was shown to allosterically regulate 5-HT signal transduction [3], onto GABA-A receptors [5], and onto glial gap junctions [4], while its biosynthesis from N-oleoylglycine was worked out in cell models [11][14]. Reviews by Boger and colleagues consolidated it as the prototypical fatty acid primary amide and a template for FAAH-directed drug design [6].
Reputation
Among neuroscientists oleamide enjoys a strong reputation as a genuinely fascinating endogenous lipid: it is the molecule that revived the search for a chemical sleep factor, the substrate that led to the discovery of FAAH, and a rare example of a lipid that reaches across cannabinoid, serotonergic, GABAergic, and gap-junction signaling at once. That scientific pedigree, however, sits uneasily beside its status as a consumer supplement. The elegant discovery biology is almost entirely preclinical, carried out in cats, rats, and cultured cells, and there is little controlled human data to show that swallowing oleamide capsules reliably improves sleep or anxiety in people. It is best understood, then, as a compound whose importance to basic neuroscience far outstrips the strength of its evidence as an over-the-counter sleep aid.
Subjective profileweighing the evidence above
Plausible but unproven. The sleep-onset work is animal, no controlled trial defines a human dose, and the 100 to 300 mg on labels is essentially guesswork. Low risk on its own for a short trial, but it is sedating and adds to alcohol, benzodiazepines and other sleep aids, so it should not be stacked blindly.
Resources
This entry is here for reference.
Research
- 1995first citedChemical characterization of a family of brain lipids that induce sleep.
- 1998most active year3 papers
- 2025most recentPharmacological characterization of cannabidiol as a negative allosteric modulator of the 5-HT2…
- 1.Chemical characterization of a family of brain lipids that induce sleep.
- 2.Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides.
- 3.Unique allosteric regulation of 5-hydroxytryptamine receptor-mediated signal transduction by oleamide.
- 4.The sleep-inducing lipid oleamide deconvolutes gap junction communication and calcium wave transmission in glial cells.
- 5.Modulation of GABA(A) receptors and inhibitory synaptic currents by the endogenous CNS sleep regulator cis-9,10-octadecenoamide (cOA).
- 6.Oleamide: an endogenous sleep-inducing lipid and prototypical member of a new class of biological signaling molecules.
- 7.Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase.
- 8.Characterization of the hypnotic properties of oleamide.
- 9.Fatty acid amide hydrolase expression in rat choroid plexus: possible role in regulation of the sleep-inducing action of oleamide.
- 10.The sleep lipid oleamide may represent an endogenous anticonvulsant: an in vitro comparative study in the 4-aminopyridine rat brain-slice model.
- 11.Oleic acid derived metabolites in mouse neuroblastoma N18TG2 cells.
- 12.In vivo evidence that N-oleoylglycine acts independently of its conversion to oleamide.
16 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
Is oleamide the same thing the body makes to help us sleep?
Yes; oleamide is an endogenous fatty acid primary amide that accumulates in cerebrospinal fluid during sleep deprivation and induces physiological sleep in animals, which is why it is considered a candidate natural sleep factor [1][8]. Whether swallowed supplements reproduce that effect in humans is not well established.
Does oleamide work like cannabis?
How is oleamide related to anandamide?
Limitations of the evidence
- Human side-effect data are essentially absent, so uncommon or long-term risks are simply unknown.
Adverse effects
- Drowsiness and reduced alertness are the most likely effects given its sleep-inducing, locomotor-suppressing action in animals.
- Additive sedation is plausible when combined with alcohol, benzodiazepines, cannabis, or other sleep aids.
Notes and cautions
- Product quality varies because much marketed oleamide is the same synthetic grade used industrially as a plastics slip agent.